



Office de la Propriété

Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2535584 A1 2005/02/24

(21) 2 535 584

(12) DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION

(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2004/08/13
(87) Date publication PCT/PCT Publication Date: 2005/02/24
(85) Entrée phase nationale/National Entry: 2006/02/13
(86) N° demande PCT/PCT Application No.: US 2004/026393
(87) N° publication PCT/PCT Publication No.: 2005/016946
(30) Priorités/Priorities: 2003/08/13 (US60/481,226);
2003/10/30 (US60/515,580); 2003/11/14 (US60/519,943);
2003/11/25 (US60/525,295)


(51) Cl.Int./Int.Cl. C07F 15/00 (2006.01),
A61P 35/00 (2006.01)

(71) Demandeur/Applicant:
UNIVERSITY OF SOUTH FLORIDA, US

(72) Inventeurs/Inventors:
KAY, HEIDI, US;
PALMER, JAY W., US;
STANKO, JOSEPH A., US

(74) Agent: MBM & CO.

(54) Titre : COMPLEXES DE PLATINE ET PROCEDES D'UTILISATION
(54) Title: PLATINUM COMPLEXES FOR THE TREATMENT OF TUMORS



(57) Abrégé/Abstract:

The subject invention concerns platinum complexes that exhibit antitumor cell/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
24 February 2005 (24.02.2005)

PCT

(10) International Publication Number
WO 2005/016946 A3

(51) International Patent Classification⁷: **C07F 15/00**, A61P 35/00

(21) International Application Number: PCT/US2004/026393

(22) International Filing Date: 13 August 2004 (13.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/481,226	13 August 2003 (13.08.2003)	US
60/515,580	30 October 2003 (30.10.2003)	US
60/519,943	14 November 2003 (14.11.2003)	US
60/525,295	25 November 2003 (25.11.2003)	US

(71) Applicant (for all designated States except US): **UNIVERSITY OF SOUTH FLORIDA** [US/US]; 4202 East Fowler Avenue, FAO 126, Tampa, FL 33620 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KAY, Heidi** [US/US]; 28550 Fairweather Drive, Wesley Chapel, FL 33543 (US). **PALMER, Jay, W.** [US/US]; 202 Bedford Trail E101, Sun City Center, FL 32573-6061 (US). **STANKO, Joseph, A.** [US/US]; 6110 110th Avenue, Temple Terrace, FL 33617 (US).

(74) Agents: **PACE, Doran, R.** et al.; P.O. Box 142950, Gainesville, FL 32614-2950 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report: 29 September 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/016946 A3

(54) Title: PLATINUM COMPLEXES FOR THE TREATMENT OF TUMORS



(1)

(57) Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism *in vivo* or *in vitro*.

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME 1 DE 2

NOTE: Pour les tomes additionnels, veillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**

THIS IS VOLUME 1 OF 2

NOTE: For additional volumes please contact the Canadian Patent Office.

DESCRIPTIONPLATINUM COMPLEXES AND METHODS OF USE

5

Cross-Reference to Related Applications

This application claims the benefit of U.S. Provisional Application Serial No. 60/481,226, filed August 13, 2003, U.S. Provisional Application Serial No. 60/515,580, filed October 30, 2003, U.S. Provisional Application Serial No. 60/525,295, filed November 25, 2003, and U.S. Provisional Application Serial No. 60/519,943, filed November 14, 2003, the disclosure of each of which is incorporated herein by reference in its entirety.

10

Background of the Invention

Cellular responses to growth factors and cytokines are characterized by activation of the Signal Transducer and Activator of Transcription (STAT) family of cytoplasmic transcription factors (Darnell, 1997; Darnell *et al.*, 1994; Schindler *et al.*, 1995; Stark *et al.*, 1998; Smithgall *et al.*, 2000; Akira, 2000; Hirano *et al.*, 2000; Bromberg *et al.*, 1996; Fukada *et al.*, 1996; Kotenko *et al.*, 2000). STATs are activated at a very early stage involving protein tyrosine kinase phosphorylation of tyrosine of growth factor receptors, receptor-associated Janus kinase (Jaks) or Src kinase families. This in turn induces phosphotyrosine (pTyr)-SH2 interactions between two STAT monomers in the formation of dimers, translocation to the nucleus, and binding to specific DNA response elements regulating gene expression essential for cell proliferation, differentiation, development and survival.

15

20

25

30

Normal STAT activation is tightly-regulated and has a short duration, which is in keeping with normal cellular requirements for mounting a response to external stimuli. However, persistent activation of specific STAT proteins, particularly Stat3 and Stat5, occurs with high frequency in some tumors and has a causal role in malignant transformation by promoting growth and survival of transformed and tumor cells, including those breast, prostate and head and neck squamous carcinoma cells, lymphomas and leukemias (Bromberg *et al.*, 1999; Turkson *et al.*, 1998; Bromberg *et al.*, 1998; Catlett-Falcone *et al.*, 1999a; Garcia *et al.*, 2001; Grandis *et al.*, 2000; Grandis *et al.*, 1998; Nielsen *et al.*, 1997; Nielsen *et al.*, 1999; Epling-Burnette *et al.*, 2001; reviewed in Bowman *et al.*, 2000; Turkson *et al.*, 2000; Song *et al.*, 2000; Coffer *et al.*, 2000; Lin *et al.*, 2000; Catlett-Falcone *et al.*, 1999b; Garcia *et*

al., 1998). Of clinical importance, blockade of aberrant Stat3 signaling in malignant cells and whole tumors that contain them induces apoptosis and tumor regression.

Platinum complexes, the prototype of cisplatin (Cis-Pt), have been widely used as active anticancer agents (Ardizzone *et al.*, 1999; Nitiss, 2002) in a variety of human tumors, 5 including testicular, ovarian, bladder carcinoma, head and neck, and non-small cell lung cancers. The outcome of treatments with cisplatin and other platinum-containing compounds is strongly linked to their alkylating effects on DNA. However, the potential impact of platinum-complex-based therapy on cellular signaling and the therapeutic importance of such interactions have yet to be explored. Reports show that cisplatin induces activation of 10 members of the mitogen-activated protein kinase (MAPK) pathways (Persons *et al.*, 1999; Sanchez-Perez *et al.*, 1998), which may influence drug-induced apoptosis.

Brief Summary of the Invention

The subject invention concerns platinum complexes and uses thereof. The platinum complexes of the invention can be used to treat oncological, viral, bacterial, and parasitic 15 disease conditions.

Brief Description of the Figures

Figure 1 shows the results in graph form from an MTT assay. Cisplatin is also 20 designated as “Cis-Pt.”

Figure 2 shows the results in graph form from an MTT assay. Cisplatin is also designated as “Cis-Pt.”

Figure 3 shows the results in graph form from an XTT assay. Cisplatin is also designated as “Cis-Pt.”

25 **Figure 4** shows the results in graph form from an MTT assay. Cisplatin is also designated as “Cis-Pt.”

Figures 5A-C show inertness of CPA-7 platinum complex to reduction by glutathione. 20 μ m CPA-7 in PBS/20% DMSO with 10 mm glutathione. As shown in Figure 30 5A, linear portions were measured at night (dark room) whereas reduction occurred in daytime. CPA-7 is not appreciably reduced by GSH but by light. As shown in Figure 5B-C, scanning kinetics over two hours shows little change. Reduction is attributed to room light.

Figure 6 shows the results in graph form from an MTT assay. Cisplatin is also designated as “Cis-Pt.”

Figure 7 shows the results in graph form from an XTT assay. Cisplatin is also designated as "Cis-Pt."

Figure 8 shows the results in graph form from an MTT assay. The figure legend identifies the $\text{Pt}(\text{NO}_2)(\text{NH}_3)_2(\text{Cl})_2\text{A}$ platinum complex by the "A" substituent identified herein. Cisplatin is also designated as "Cis-Pt." Two different isolates of the platinum (IV) complex substituted with Safranin were isolated (referred to herein as Safranin 1 and Safranin 2) and tested in the assay.

Figure 9 shows the results in graph form from an MTT assay. The figure legend identifies the $\text{Pt}(\text{NO}_2)(\text{NH}_3)_2(\text{Cl})_2\text{A}$ platinum complex by the "A" substituent identified herein. Cisplatin is also designated as "Cis-Pt." Two different isolates of the platinum (IV) complex substituted with Safranin were isolated (referred to herein as Safranin 1 and Safranin 2) and tested in the assay.

Figure 10 shows the results in graph form from an XTT assay. The figure legend identifies the $\text{Pt}(\text{NO}_2)(\text{NH}_3)_2(\text{Cl})_2\text{A}$ platinum complex by the "A" substituent identified herein. Cisplatin is also designated as "Cis-Pt."

Figure 11 shows the results in graph form from an MTT assay. The figure legend identifies the $\text{Pt}(\text{NO}_2)(\text{NH}_3)_2(\text{Cl})_2\text{A}$ platinum complex by the "A" substituent identified herein. Cisplatin is also designated as "Cis-Pt."

Figures 12A-B are photographs showing nuclear extracts containing activated Stat1 and Stat3 are treated with the indicated concentrations of other platinum (IV) complexes (designated herein as HK 104, HK 105, HK 106, HK 107, HK 108, HK 109, HK 110, HK 111, and HK 112) for 30 min at room temperature prior to incubation with radiolabeled hSIE oligonucleotide probe. Stat1 and Stat3 binding activities to hSIE probe are shown.

25

Brief Description of the Sequence

SEQ ID NO:1 is the nucleotide sequence of an oligonucleotide probe.


Detailed Disclosure of the Invention

The subject invention concerns platinum complexes and uses thereof. Platinum complexes of the invention can induce apoptosis and/or inhibit tumor cell growth and can also be used to treat cancers. The platinum complexes of the invention also can be used as antiviral, antibacterial, and antiparasitic agents. It has been suggested that cellular cytotoxicity of platinum (IV) compounds is a result of platinum (IV) compounds being

reduced to platinum (II) in the cell. Surprisingly, platinum (IV) complexes of the present invention may not require this type of reduction in the cells to have a cytotoxic effect. Therefore, the platinum complexes of the present invention are distinct from platinum compounds in the art by maintaining their correct oxidative conformation as platinum (IV) compounds which are more effective than the existing platinum (II) compounds. In addition, platinum complexes of the invention can also form nitric oxide in the cells as radicals thereby killing the cells through the formation of oxide radicals.


Platinum complexes of the invention include those complexes having the structure shown in formula I:

10




wherein


15 X and Y are, independently, any halogen, $-\text{NO}_2$, $-\text{ONO}$, or the structure:



20 or X and Y together form the structure:




or



25

30

or




;

R^1 is $-NO_2$ or $-ONO$;

R^2 is any halogen, $-OH$, $-ONO$, $-ONO_2$, $-COR^{10}$, $-OPO_3R^{10}R^{11}$, $-OSO_3H$, $-OSeOOH$, $-SeOOH$,

5 $-AsO_2$, $-OAsO_2$, $-NR^{10}R^{11}$, $-NHR^{10}R^{11}$, $-OOCR^{15}$, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl, any of which can be optionally substituted with any halogen, $-COOH$, $-OH$, $-NO_2$, $-NH_2$, $-N$ -alkyl, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl, or the structure:

15



any of which can be substituted with any halogen, $-NH_2$, $-COOH$, $-OH$, alkoxy, cycloalkoxy; R^3 is, independently, $-NH_3$, or $-NHR^7$;

20 R^7 is H, C_{1-6} alkyl, alkoxy, or aryl, optionally substituted with $-NO_2$ or $-COOH$; R^{10} and R^{11} are, independently, H, $-NH_2$, $-OH$, $-NHR^7$, $CONHR^7$, $CON(R^7)_2$, C_{1-6} alkyl, aryl, or heteroaryl, any of which can be optionally substituted with any halogen, $-COOH$, $-OH$, $-NO_2$,

25 $-NH_2$, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl;


30 R^{15} is alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl, any of which can be optionally substituted with any halogen, $-COOH$, $-OH$, $-NO_2$, $-NH_2$, $-N$ -alkyl, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl,

heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl; or a pharmaceutically acceptable salt thereof.

In one embodiment, X and Y can be, independently, fluorine (F), chlorine (Cl),
5 bromine (Br) or iodine (I). In an exemplified embodiment, X is Cl and Y is Cl.


In one embodiment, R¹ is -NO₂, R² is Cl and R³ is -NH₃.

Platinum complexes of the invention can also have the structure shown in formula II:





wherein

15 X and Y are, independently, any halogen, or the structure:




20 or X and Y together form the structure:






or



5

or


10



;

15 R⁴ is -NO₂ or -ONO;


R⁵ is any halogen, -OH, -ONO, -ONO₂, -COR¹⁰, -OPO₃R¹⁰R¹¹, -OSO₃H, -OSeOOH, -SeOOH, -AsO₂, -OAsO₂, -NR¹⁰R¹¹, -NHR¹⁰R¹¹, -OOCR¹⁵, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxy carbonyl, cycloalkyl carbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkyl carbonyl, heteroaryl, aryl carbonyl, heteroaryl carbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl, any of which can be optionally substituted with any halogen, -COOH, -OH, -NO₂, -NH₂, -N-alkyl, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxy carbonyl, cycloalkyl carbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkyl carbonyl, heteroaryl, aryl carbonyl, heteroaryl carbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl, or the structure:



30


any of which can be substituted with any halogen, -NH₂, -COOH, -OH, or Y and R⁵ form the structure:

5



10

or X, Y, and R⁵ together form the structure:



15

R⁶ is, independently, NH₂ or NH;

R⁷ is H, C₁₋₆ alkyl, alkoxy, aryl, optionally substituted with -NO₂ or -COOH;

R⁸ and R⁹ are, independently, H, C₁₋₆ alkyl, or -OH, any of which can be optionally substituted with any halogen, -COOH, -OH, -NO₂, -NH₂, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl;

R¹⁰ and R¹¹ are, independently, H, -NH₂, -OH, -NHR⁷, CONHR⁷, CON(R⁷)₂, C₁₋₆ alkyl, aryl, or heteroaryl, any of which can be optionally substituted with any halogen, -COOH, -OH, -NO₂,

-NH₂, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl;

R¹² and R¹³ are, independently, H or C₁₋₆ alkyl, or R¹² and R¹³ together form an aryl, cycloalkyl, heterocycloalkyl, or heteroaryl, any of which can be optionally substituted with any halogen, -COOH, -OH, -NO₂, -NH₂, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl;



R¹⁵ is alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl,

arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl, any of which can be optionally substituted with any halogen, -COOH, -OH, -NO₂, -NH₂, -N-alkyl, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl; n is any integer from 0 to 6; or a pharmaceutically acceptable salt thereof.

In one embodiment, X and Y can be, independently, fluorine (F), chlorine (Cl), bromine (Br) or iodine (I). In an exemplified embodiment, X is Cl and Y is Cl.


In one embodiment, R⁴ is -NO₂, R⁵ is Cl, R⁶ is -NH₂, and n is 0.

Platinum complexes of the invention can also have the structure shown in formula III or IV:




wherein

20 X and Y are, independently, any halogen, -NO₂, -ONO, or X and Y together form the structure:



or



;

25 R⁶ is, independently, NO₂, N, NH, or NH₂;

30 R⁸ and R⁹ are, independently, H, C₁₋₆ alkyl, or -OH, any of which can be optionally substituted with any halogen, -COOH, -OH, -NO₂, -NH₂, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl,

heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroalkyloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl; R¹² and R¹³ are, independently, H or C₁₋₆ alkyl, or R¹² and R¹³ together form an aryl, cycloalkyl, heterocycloalkyl, or heteroaryl, any of which can be optionally substituted with any halogen, -COOH, -OH, -NO₂, -NH₂, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxy carbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl;



n is any integer from 0 to 6;

10 or a pharmaceutically acceptable salt thereof.

In one embodiment, X and Y can be, independently, fluorine (F), chlorine (Cl), bromine (Br) or iodine (I). In an exemplified embodiment, X is Cl and Y is Cl.

Also contemplated within the scope of the invention are platinum complexes that are not defined by formula I or formula II but that are specifically exemplified in the Table 5 presented herein. Exemplified embodiments of platinum complexes of the invention are shown in Table 5. The chemical structure of a complex along with a designation name (e.g., CPA-XX) is shown in the Table. Alternative designation names (e.g., HKXXX) of a complex are shown in parentheses.

Platinum complexes of the invention also include those complexes having the structure shown in formula V or formula VI:




wherein

X and Y are, independently, any halogen, -OH, H₂O, or -SO(CH₃)₂;

and A can be any of the following:

11


5



(safranin)

or


10



(methylene blue)

or


15



20

(caffeine)


or



(N-acetyl galactosamine)

or


25




(N-acetyl glucosamine)

30 or


12



or




or



or


30

13



(theophylline)


or



(hydantoin)


10

or



(theobromine)


or



(thiamine hydrochloride)


20

or



(alpha-aminoisobutyric acid)

or




(7-ethoxycoumarin)

30

or


5



10

(riboflavin)


or



(cytarabine)

or


15



20

(xanthine)

or



(inosine)

and wherein

R¹ is, independently, NH₂ or NH;

25 R² and R³ are, independently, H, -OH, C₁₋₆ alkyl, alkoxy, cycloalkyl, aryloxy, cycloalkoxy, aryl, heteroalkyl, heterocycloalkyl, heteroaryl, arylcarbonyl, and heteroarylcarbonyl, any of which can be optionally substituted with alkyl, alkoxy, cycloalkyl, aryloxy, cycloalkoxy, aryl, heteroalkyl, heterocycloalkyl, heteroaryl, arylcarbonyl, and heteroarylcarbonyl.

30 R⁴ and R⁵ are, independently, H or C₁₋₆ alkyl, alkoxy, cycloalkyl, aryloxy, cycloalkoxy, aryl, heteroalkyl, heterocycloalkyl, heteroaryl, arylcarbonyl, and heteroarylcarbonyl or R⁴ and R⁵ together form a cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryl, arylcarbonyl, and heteroarylcarbonyl, any of which can be optionally substituted with alkyl,

alkoxy, cycloalkyl, aryloxy, cycloalkoxy, aryl, heteroalkyl, heterocycloalkyl, heteroaryl, arylcarbonyl, and heteroarylcarbonyl;
n is any integer from 0 to 6;
or a pharmaceutically acceptable salt thereof.

5 In one embodiment, X and Y can be, independently, chlorine (Cl), bromine (Br) or iodine (I). In an exemplified embodiment, X is Cl and Y is Cl.

As used herein, alkyl means straight or branched chain, saturated or mono- or polyunsaturated hydrocarbon groups having from 1 to 20 carbon atoms and C_{1-X} alkyl means straight or branched chain alkyl groups containing from one up to X carbon atoms. For 10 example, C₁₋₆ alkyl means straight or branched chain alkyl groups containing from one up to 6 carbon atoms. Alkoxy means an alkyl-O-group in which the alkyl group is as previously described. Cycloalkyl includes a nonaromatic monocyclic or multicyclic ring system, including fused and spiro rings, of from about three to about 10 carbon atoms. A cyclic alkyl may optionally be partially unsaturated. Cycloalkoxy means a cycloalkyl-O-group in which 15 cycloalkyl is as defined herein. Aryl means an aromatic monocyclic or multicyclic carbocyclic ring system, including fused and spiro rings, containing from about six to about 14 carbon atoms. Aryloxy means an aryl-O-group in which the aryl group is as described herein. Alkylcarbonyl means a RC(O)- group where R is an alkyl group as previously described. Alkoxycarbonyl means an ROC(O)- group where R is an alkyl group as 20 previously described. Cycloalkylcarbonyl means an RC(O)- group where R is a cycloalkyl group as previously described. Cycloalkoxycarbonyl means an ROC(O)- group where R is a cycloalkyl group as previously described.

Heteroalkyl means a straight or branched-chain having from one to 20 carbon atoms and one or more heteroatoms selected from nitrogen, oxygen, or sulphur, wherein the 25 nitrogen and sulphur atoms may optionally be oxidized, *i.e.*, in the form of an N-oxide or an S-oxide. Heterocycloalkyl means a monocyclic or multicyclic ring system (which may be saturated or partially unsaturated), including fused and spiro rings, of about five to about 10 elements wherein one or more of the elements in the ring system is an element other than carbon and is selected from nitrogen, oxygen, silicon, or sulphur atoms. Heteroaryl means a 30 five to about a 14-membered aromatic monocyclic or multicyclic hydrocarbon ring system, including fused and spiro rings, in which one or more of the elements in the ring system is an element other than carbon and is selected from nitrogen, oxygen, silicon, or sulphur and wherein an N atom may be in the form of an N-oxide. Arylcarbonyl means an aryl-CO-group

in which the aryl group is as described herein. Heteroarylcarbonyl means a heteroaryl-CO-group in which the heteroaryl group is as described herein and heterocycloalkylcarbonyl means a heterocycloalkyl-CO-group in which the heterocycloalkyl group is as described herein. Aryloxycarbonyl means an ROC(O)- group where R is an aryl group as previously described. Heteroaryloxycarbonyl means an ROC(O)- group where R is a heteroaryl group as previously described. Heterocycloalkoxy means a heterocycloalkyl-O- group in which the heterocycloalkyl group is as previously described. Heterocycloalkoxycarbonyl means an ROC(O)- group where R is a heterocycloalkyl group as previously described.

Examples of saturated alkyl groups include, but are not limited to, methyl, ethyl, N-propyl, isopropyl, N-butyl, tert-butyl, isobutyl, sec-butyl, N-pentyl, N-hexyl, N-heptyl, and N-octyl. An unsaturated alkyl group is one having one or more double or triple bonds. Unsaturated alkyl groups include, for example, ethenyl, propenyl, butenyl, hexenyl, vinyl, 2-propynyl, 2-isopentenyl, 2-butadienyl, ethynyl, 1-propynyl, 3-propynyl, and 3-butynyl. Cycloalkyl groups include, for example, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, and cycloheptyl. Heterocycloalkyl groups include, for example, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 3-morpholinyl, 4-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and 1,4-diazabicyclooctane. Aryl groups include, for example, phenyl, indenyl, biphenyl, 1-naphthyl, 2-naphthyl, anthracenyl, and phenanthracenyl. Heteroaryl groups include, for example, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, pyridyl, indolyl, quinolinyl, isoquinolinyl, benzoquinolinyl, carbazolyl, and diazaphenanthrenyl.

As used herein, halogen means the elements fluorine (F), chlorine (Cl), Bromine (Br), and iodine (I).

The term pharmaceutically-acceptable salts means salts of the platinum complexes of the invention which are prepared with acids or bases, depending on the particular substituents present on the subject complexes described herein. Examples of a pharmaceutically-acceptable base addition salts include sodium, potassium, calcium, ammonium, or magnesium salt. Examples of pharmaceutically-acceptable acid addition salts include hydrochloric, hydrobromic, nitric, phosphoric, carbonic, sulphuric, and organic acids like acetic, propionic, benzoic, succinic, fumaric, mandelic, oxalic, citric, tartaric, maleic, and the like. Pharmaceutically-acceptable salts of platinum complexes of the invention can be prepared using conventional techniques.

It will be appreciated by those skilled in the art that certain of the platinum complexes of the invention may contain one or more asymmetrically substituted carbon atoms which can give rise to stereoisomers. All such stereoisomers, including enantiomers, and diastereoisomers and mixtures, including racemic mixtures thereof, are contemplated within the scope of the present invention.

Platinum complexes of the present invention are potent and selective disruptors of STAT activity. The complexes designated herein as CPA-7, CPA-10, CPA-39 (HK104), CPA-43 (HK106), CPA-46 (HK111), CPA-51 (HK110), CPA-55 (HK109), CPA-30 (HK112), and CPA-41 strongly disrupt Stat3 activity and interfere with its ability to bind to its consensus binding sequence. Platinum complexes of the invention can induce cell growth inhibition and apoptosis in transformed and tumor cells with persistently active STATs. Malignant cells with aberrant or constitutive STAT signaling are highly sensitive to platinum complexes of the invention. General cytotoxicity of the subject platinum complexes to normal cells is minimal or nil. In addition, strong apoptosis is induced by platinum compounds of the invention in malignant cells that harbor persistently-active STAT signaling, which correlates with suppression of aberrant STAT activity in these cells.

Platinum complexes of the invention also exhibit anti-tumor activity in melanoma and colon tumors *in vivo*. The abrogation of constitutively-active STATs in tumors treated with platinum complexes of the invention is consistent with their effects on STAT activity both *in vitro* and in whole cells, and together establish STAT-based anti-tumor effects of these compounds.

Methods of the invention comprise inhibiting function of a STAT by contacting a cell expressing a STAT with a platinum complex of the invention wherein the complex is taken in or otherwise provided inside the cell. Platinum complexes of the invention can physically interact with the DNA-binding domain of Stat3 and thereby disrupts its ability to bind to DNA. In Src-transformed mouse fibroblasts, as well as in human tumor cells of the breast, prostate, and mouse melanoma cells that contain constitutive Stat3 activity, both CPA-1 and CPA-7 abrogate Stat3 signaling function and thereby induce cell growth inhibition and apoptosis.

Methods of the invention also comprise inhibiting the function and/or growth and replication of a cell that is aberrantly or constitutively expressing a STAT, such as Stat1 or Stat3. In one embodiment, the method comprises contacting a cell with a platinum complex of the invention. In one embodiment, the cell is a tumor cell, cancer cell, or a transformed

cell. The cell can be a cell from a mammal, including human, monkey, chimpanzee, ape, dog, cat, cow, pig, and horse.

Platinum complexes of the invention can be delivered to a cell either through direct contact with the cell or via a carrier means. Carrier means for delivering compositions to cells are known in the art and include, for example, encapsulating the composition in a liposome moiety. Another means for delivery of platinum complexes of the invention to a cell comprises attaching the platinum complexes to a protein or nucleic acid that is targeted for delivery to the target cell. Published U.S. Patent Application Nos. 20030032594 and 20020120100 disclose amino acid sequences that can be coupled to another composition and that allows the composition to be translocated across biological membranes. Published U.S. Patent Application No. 20020035243 also describes compositions for transporting biological moieties across cell membranes for intracellular delivery.

The subject invention also concerns methods for treating oncological or inflammatory disorders in a patient. In one embodiment, an effective amount of a platinum complex of the present invention is administered to a patient having an oncological or inflammatory disorder and who is in need of treatment thereof. Methods of the invention can optionally include identifying a patient who is or may be in need of treatment of an oncological or inflammatory disorder. The patient can be a human or other mammal, such as a primate (monkey, chimpanzee, ape, *etc.*), dog, cat, cow, pig, or horse, or other animals having an oncological disorder. Means for administering and formulating platinum complexes for administration to a patient are known in the art, examples of which are described herein. Oncological disorders include cancer and/or tumors of the bone, breast, kidney, mouth, larynx, esophagus, stomach, testis, cervix, head, neck, colon, ovary, lung, bladder, skin, liver, muscle, pancreas, prostate, blood cells (including lymphocytes), and brain. Inflammatory disorders include arthritis, multiple sclerosis, lupus, Crohn's disease, and related neurological and inflammatory connective tissue diseases (*e.g.*, Sjögren's syndrome).

For the treatment of oncological disorders, the platinum complexes of this invention can be administered to a patient in need of treatment in combination with other antitumor or anticancer substances or with radiation therapy or with surgical treatment to remove a tumor. These other substances or radiation treatments may be given at the same as or at different times from the platinum complexes of this invention. For example, the platinum complexes of the present invention can be used in combination with mitotic inhibitors such as taxol or vinblastine, alkylating agents such as cyclophosphamide or ifosfamide, antimetabolites such as

5-fluorouracil or hydroxyurea, DNA intercalators such as adriamycin or bleomycin, topoisomerase inhibitors such as etoposide or camptothecin, antiangiogenic agents such as angiostatin, antiestrogens such as tamoxifen, and/or other anti-cancer drugs or antibodies, such as, for example, GLEEVEC (Novartis Pharmaceuticals Corporation) and HERCEPTIN (Genentech, Inc.), respectively.

Many tumors and cancers have viral genome present in the tumor or cancer cells. For example, Epstein-Barr Virus (EBV) is associated with a number of mammalian malignancies. The platinum complexes of the subject invention can be used alone or in combination with anticancer or antiviral agents, such as ganciclovir, azidothymidine (AZT), lamivudine (3TC), 10 *etc.*, to treat patients infected with a virus that can cause cellular transformation and/or to treat patients having a tumor or cancer that is associated with the presence of viral genome in the cells. The platinum complexes of the subject invention can also be used in combination with viral based treatments of oncologic disease. For example, platinum complexes of the invention can be used with mutant herpes simplex virus in the treatment of non-small cell 15 lung cancer (Toyoizumi *et al.*, 1999).

The subject invention also concerns methods for treating bacterial and viral infections of a patient using a platinum complex of the invention. In one embodiment, an effective amount of a platinum complex of the invention is administered to a patient having a bacterial or viral infection. Methods of the invention can optionally include identifying a patient who 20 is or may be in need of treatment of a bacterial or viral infection. The patient can be a human or other mammal, such as a primate (monkey, chimpanzee, ape, *etc.*), dog, cat, cow, pig, or horse, or other animal infected with a bacteria or virus. Bacterial infections that can be treated according to the present invention include those from *Staphylococcus*, *Streptococcus*, *Salmonella*, *Bacillus*, *Clostridium*, *Pseudomonas*, *Neisseria*, *Mycobacterium*, 25 and *Yersinia*. Viral infections that can be treated according to the present invention include, but are not limited to, those associated with human immunodeficiency virus (HIV), human T cell leukemia virus (HTLV), Papillomavirus (*e.g.*, human papilloma virus), Polyomavirus (*e.g.*, SV40, BK virus, DAR virus), orthopoxvirus (*e.g.*, variola major virus (smallpox virus)), EBV, herpes simplex virus (HSV), hepatitis virus, Rhabdovirus (*e.g.*, Ebola virus) and 30 cytomegalovirus (CMV). Platinum compositions of the present invention can also be used to treat viral diseases in the presence of photodynamic therapy (Cuny *et al.*, 1999). Platinum complexes of the present invention which can be used in photodynamic therapy include, but are not limited to, the complexes designated herein as CPA-30, CPA-32, CPA-38, CPA-39,

CPA-41, CPA-42, CPA-43, CPA-45, CPA-46, CPA-51, CPA-53, CPA-54, CPA-55, and JP5. It is contemplated that these compounds are activated by light to activate their antiviral, antibacterial, antitumor, antiparasitic, or cellular effects.

Platinum complexes of the subject invention can also be used to treat patients infected with a parasitic organism. In one embodiment, the patient is administered a therapeutically effective amount of a platinum complex of the present invention. Methods of the invention can optionally include identifying a patient who is or may be in need of treatment of a parasitic infection. The patient can be a human or other mammal, such as a primate (monkey, chimpanzee, ape, *etc.*), dog, cat, cow, pig, or horse, or other animal infected with a parasitic organism. Disease conditions that can be treated according to the present invention include, but are not limited to, *leishmania*, toxoplasmosis, schistosomiasis, trypanosomiasis, pneumocystis, malaria, and trichinosis. Parasitic organisms that can cause disease conditions treatable according to the present invention include, but are not limited to, *Leishmania*, *Toxoplasma*, *Schistosoma*, *Plasmodium*, and *Trypanosoma*. The subject invention can also be used to treat gastro-intestinal disorders caused by parasitic organisms such as, *Entamoeba*, *Giardia*, *Trichomonas*, and nematodes such as *Ascaris*, *Trichuris*, *Enterobius*, *Necator*, *Ancylostoma*, *Strongyloides*, and *Trichinella*. In another embodiment, a platinum complex of the present invention can be administered to patients prophylactically, wherein an uninfected patient is traveling to or will be present in an area where parasitic disease is prevalent or poses a risk to the patient. Accordingly, the patient can be treated with a composition of the present invention prior to the patient's exposure to or presence in the area where parasitic disease is prevalent or poses a risk and/or prior to infection with the parasitic organism.

Platinum complexes of the present invention can also be used to treat biological products *in vitro* that are contaminated with or suspected of being contaminated with a virus on a bacterial or parasitic organism. Biological products which can be treated with a platinum complexes of the present invention include, but are not limited to, whole blood, fractionated blood, plasma, serum, whole organs, or parts of organs, and cells, including blood cells, muscle cells, skin cells, and neural cells, and products derived from cells. Products derived from cells which can be treated with a platinum complex of the present invention include, but are not limited to, interferons, interleukins, blood clotting factors such as factor VIII, IX, X, and the like, insulin, polyclonal and monoclonal antibodies, growth factors, cytokines, and other products. Treatment of biological products comprises contacting the product for an effective amount of time and with an effective amount of a platinum

complex of the present invention. If necessary, the biological product can be subsequently washed, preferably with a suitable sterile wash solution such as phosphate buffered saline, to remove the platinum complex that was used to treat the product.

Therapeutic application of the subject platinum complexes, and compositions containing them, can be accomplished by any suitable therapeutic method and technique presently or prospectively known to those skilled in the art. The subject platinum complexes can be administered by any suitable route known in the art including, for example, oral, nasal, rectal, and parenteral routes of administration. As used herein, the term parenteral includes subcutaneous, intradermal, intravenous, intramuscular, intraperitoneal, and intrasternal administration, such as by injection. Administration of the subject platinum complexes of the invention can be continuous or at distinct intervals as can be readily determined by a person skilled in the art.

Platinum complexes of the subject invention can be formulated according to known methods for preparing pharmaceutically useful compositions. Formulations are described in detail in a number of sources which are well known and readily available to those skilled in the art. For example, *Remington's Pharmaceutical Science* by E.W. Martin describes formulations which can be used in connection with the subject invention. In general, the compositions of the subject invention will be formulated such that an effective amount of the bioactive platinum complex is combined with a suitable carrier in order to facilitate effective administration of the composition. The compositions used in the present methods can also be in a variety of forms. These include, for example, solid, semi-solid, and liquid dosage forms, such as tablets, pills, powders, liquid solutions or suspension, suppositories, injectable and infusible solutions, and sprays. The preferred form depends on the intended mode of administration and therapeutic application. The compositions also preferably include conventional pharmaceutically acceptable carriers and diluents which are known to those skilled in the art. Examples of carriers or diluents for use with the subject platinum complexes include ethanol, dimethyl sulfoxide, glycerol, alumina, starch, and equivalent carriers and diluents. To provide for the administration of such dosages for the desired therapeutic treatment, pharmaceutical compositions of the invention will advantageously comprise between about 0.1% and 99%, and especially, 1 and 15% by weight of the total of one or more of the subject platinum complexes based on the weight of the total composition including carrier or diluent.

The platinum complexes of the subject invention can also be administered utilizing liposome technology, slow release capsules, implantable pumps, and biodegradable containers. These delivery methods can, advantageously, provide a uniform dosage over an extended period of time. The platinum complexes of the present invention can also be 5 administered in their salt derivative forms or crystalline forms known to those of ordinary skill in the art.

The subject invention also concerns a packaged dosage formulation comprising in one or more containers at least one platinum compound of the subject invention formulated in a pharmaceutically acceptable dosage.

10

All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.

15

Materials and Methods

Synthesis of NitroPlatinum (IV) Complexes.

Cis-diammineplatinum(II) dichloride (cisplatin) can be purchased at 99.9% purity from Sigma-Aldrich (#P4394). Using 0.300 grams of Cisplatin (0.00100 moles, FW = 300.1), 150 mL of ultra deionized water and 50 mL of dichloroethane are added to a 250-mL 20 Erlenmeyer flask. However, hexane or any organic solvents can be substituted in place of the dichlorethane used here. The choice of a sixth ligand includes the availability of a nitrogen, sulfur or oxygen atom in the chemical structure providing a Lewis base for bonding to the oxidized Pt. Other bondings are possible with metals, halides (such as HCl) or through chelation or interaction with pi molecular orbitals. One mole of the chosen ligand per mole 25 of cisplatin should be weighed and added to the mixture. Organic solvents, such as dichloroethane, provide solubility for organic ligands of hydrophobic nature. A magnetic stir bar is placed in the mixture and the flask placed on a magnetic stir plate in a chemical fume hood. A lecture bottle of dinitrogen tetroxide is fitted with a regulator and Teflon hose, with 30 a glass pipet attached to the hose outlet. The pipet tip is inserted into the lower solvent (*e.g.*, dichloroethane) and the lecture bottle warmed slightly with a warm water bath. Nitrogen dioxide gas is released at a rate of approximately one bubble per second into the stirring mixture. The gas should be added until all the yellow cisplatin is consumed; the disappearance of yellow solids and yellow solution will indicate consumption of the available

cisplatin. A blue color is noted to indicate formation of the nitrosyl intermediate; variations in hue and duration of this color have been observed. Gas addition is then terminated (remove the pipet to prevent vacuum suction into the lecture bottle) and the flask covered in aluminum foil to prevent light exposure. The flask should be left to stir overnight, 5 uncovered.

Additional nitrogen dioxide may be added the next day to check for completeness of reaction. A blue color would indicate incomplete oxidation of platinum (II). Normally, this blue fades within ten minutes. For a colorless ligand, the solution has become yellow overnight. If blue color remains, allow it to continue stirring. The mixture requires air for 10 complete oxidation, so should not be tightly covered. Continued oxidation with air can be accelerated using air blown through a trap into the Erlenmeyer, over the liquids. The solvents will evaporate in about two days, leaving a yellow precipitate, which is the product.

The precipitate can be purified via recrystallization in methanol, DMSO, or other suitable solvent. Alternatively, the product can be purified on silica columns or using HPLC.

15

MTT Assay.

1. Prepare a suspension of A549 cells at 2×10^5 cells per mL in supplemented DMEM/F12 growth medium.
2. Plate 2×10^4 cells per well in a 96 well cell culture plate by adding 100 μ L of 20 stock suspension to each well.
3. For each platinum compound (already in solution), prepare a readily usable stock solution in DMEM/F12 medium.
4. For each compound generate triplicate trials of 0, 10, 20, 30, 40, 50, 60, and 70 μ M concentration. This is achieved in situ by adding appropriate volumes of stock 25 solution to each well along with the volume of untreated medium necessary to generate the desired concentration in a final volume of 200 μ L.
5. Gently agitate plates to mix contents. Incubate at 37° C, 7 % CO₂ for 45 hours.
6. Add 20 μ L of 5mg/mL MTT solution (in PBS) to each well.
- 30 7. Gently agitate plates to mix contents and incubate an additional 3 hours to allow product development.

8. Remove plates from incubator and agitate to cause settling of formazan product.

9. Aspirate out liquid contents of each well using needle and syringe and discard.

10. Add 200 μ L DMSO to each well to dissolve formazan product.

5 11. Agitate plates until all of the formazan product is in solution and no purple crystals remain on the bottom surface of the wells.

12. Read the absorbance of each well at 475 nm using Varian software for Cary 50 UV-vis Spectrophotometer with fiber optic probe accessory.

10 XTT Assay.

A 96-well plate was used for the assays. Approximately 2.5×10^4 cells in log phase were added to each well. A platinum complex of the invention was dispensed into each well (dissolved in 20% DMSO and 80% media), with additional media added as needed to account for uniform volumes. Control wells contained only cells and media. Each concentration assay was performed in triplicate. Plates were incubated for 48 hours at 37 °C with 7.5% CO₂. XTT from MD Biosciences, Quebec, was then added according to the provided protocol concentrations and allowed to react for 3 hours. Plates were agitated 5 minutes before reading absorbance at 475 nm on a Varian Cary 50 spectrophotometer with a fibre-optic probe. Percent survival as compared to control wells was plotted against platinum complex concentration.

Nuclear extract preparation and analysis by EMSA of HK-designated platinum complexes.

Nuclear extracts were prepared from NIH3T3/hEGFR cell that overexpress human epidermal growth factor (EGF) receptor and stimulated with EGF (6 ng/ml) for 15 min. 25 Nuclear extracts were pre-incubated with compounds for 30 min at room temperature prior to incubation with radiolabeled probe. The ³²P-labeled oligonucleotide probe used is hSIE (high affinity *sis*-inducible element, m67 variant, 5'-AGCTTCATTCCCGTAAATCCCTA-3') (SEQ ID NO:1) that binds both Stat1 and Stat3.

Following are examples which illustrate procedures for practicing the invention.

30 These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

Example 1—MTT assay data for platinum complexes

MTT assays are used for the quantitative determination of cellular proliferation and activation and for the quantitation of *in vitro* tumor cell sensitivity to anti-cancer compounds. The assay is based on the cleavage of the yellow tetrazolium salt MTT into purple colored formazan by metabolically active cells. Solubilized formazan product can be photometrically quantitated using an ELISA plate reader. A decrease in the number of living cells results in a decrease in total metabolic activity which leads to a decrease in color formation. Platinum complexes of the present invention were tested in MTT assays using A549 cells to determine anti-cancer cell activity. The results are shown in Tables 1, 2, 3, and 4 and Figures 1, 2 and 10. Table 1 shows percent survival of A549 cells and Table 2 shows the IC50 from the data in Table 1. Figures 1, 2, and 4 show percent survival versus platinum complex concentration in graphical form. Figure 6 shows a graph of absorbance at 570 nm versus concentration of several platinum complexes (μM) of the invention.

Table 1. Percent of Survival of A549 Using Platinum Complex in MTT Assay

Complex	Concentration (in μM)	Percent Survival	Average Absorbance
Cis-Pt	10	98.2423	2.3196
	20	98.3779	2.3228
	30	99.6400	2.3526
	40	90.2757	2.1315
	50	78.1288	1.8447
	60	46.7536	1.1039
	70	30.1470	0.7118
CPA-7	10	99.1021	2.3399
	20	100.0974	2.3634
	30	90.6908	2.1413
	40	46.9993	1.1097
	50	20.0712	0.4739
	60	28.2750	0.6676
	70	24.3742	0.5755
CPA-46 (Rhodamine)	10	101.7831	2.4032
	20	97.3190	2.2978
	30	96.0188	2.2671
	40	78.8531	1.8618
	50	43.5602	1.0285
	60	29.8208	0.7041
	70		
CPA-31 (Citrate)	10	102.8080	2.4274
	20	99.5087	2.3495
	30	100.7073	2.3778
	40		

Table 1. Percent of Survival of A549 Using Platinum Complex in MTT Assay

	50	not	performed
	60		
	70		
CPA-43 (Dinitrophenyl Hydrazine)	10	102.2828	2.4150
	20	78.5820	1.8554
	30	90.8517	2.1451
	40	55.1861	1.3030
	50		
	60	not	performed
	70		
CPA-41 (Diphenyl Isobenzofuran)	10	100.4024	2.3706
	20	100.9148	2.3827
	30	89.4668	2.1124
	40	36.6270	0.8648
	50		
	60	not	performed
	70		
CPA-55 (Hydroorotic Acid)	10	103.6847	2.4481
	20	100.5082	2.3731
	30	98.5473	2.3268
	40	58.3626	1.3780
	50		
	60	not	performed
	70		
CPA-39 (Fluorescein)	10	107.2085	2.5313
	20	102.9478	2.4307
	30	99.9492	2.3599
	40	83.0587	1.9611
	50	43.7000	1.0318
	60	32.9338	0.7776
	70	41.4976	0.9798
CPA-51 (Luminol)	10	105.5652	2.4925
	20	109.1017	2.5760
	30	98.3186	2.3214
	40	87.3152	2.0616
	50	58.7396	1.3869
	60	37.3004	0.8807
	70	45.8219	1.0819

Table 2. Calculated IC50's from MTT Assay Data of Table 1

Complex	Calculated IC 50 (μ M concentration)	
Cisplatin	63.29	
CPA-51 (Luminol)	61.21	
CPA-39 (Fluorescein)	56.39	
CPA-46 (Rhodamine)	52.88	
CPA-55 (Hydroorotic Acid)	54.20	Extrapolated from data 10-40 μ M
CPA-43 (DNP)	49.59	Extrapolated from data 10-40 μ M
CPA-41 (IBF)	40.71	Extrapolated from data 10-40 μ M
CPA-7	45.43	
CPA-31 (Citrate)	505.81	Suspected error due to incomplete data set

Values in bold are outside the measured range.
All values are determined using a linear trend from percent survival vs. concentration data.

Table 3. Percent of Survival of A549 Using Platinum Complex in MTT Assay

Complex	Concentration (in μ M)	Percent Survival	Average Absorbance
Cis-Pt	10	100.9661	2.4665
	20	100.5199	2.4556
	30	92.8650	2.2686
	40	71.9432	1.7575
	50	52.5114	1.2828
	60	32.6293	0.7971
	70	27.5001	0.6718
CPA-7	10	100.1965	2.4477
	20	95.3703	2.3298
	30	57.9148	1.4148
	40	18.7646	0.4584
	50	17.6880	0.4321
	60	20.5166	0.5012
	70	14.2454	0.3480
CPA-46 (Rhodamine)	10	105.5017	2.5773
	20	98.7269	2.4118
	30	80.3840	1.9637
	40	49.3021	1.2044
	50	25.7153	0.6282
	60	26.3867	0.6446
	70	25.2364	0.6165
CPA-31 (Citrate)	10	103.5409	2.5294
	20	97.7322	2.3875
	30	73.5929	1.7978
	40	33.5503	0.8196
	50	24.7616	0.6049
	60	24.8352	0.6067
	70	25.4943	0.6228

Table 3. Percent of Survival of A549 Using Platinum Complex in MTT Assay

Complex	Concentration (in μ M)	Percent Survival	Average Absorbance
CPA-43 (Dinitrophenyl Hydrazine)	10	105.7759	2.5840
	20	93.8311	2.2922
	30	60.7188	1.4833
	40	26.5218	0.6479
	50	18.9979	0.4641
	60	26.6241	0.6504
	70	20.7090	0.5059
CPA-41 (Diphenyl Isobenzofuran)	10	100.2906	2.4500
	20	97.4457	2.3805
	30	60.1171	1.4686
	40	17.2336	0.4210
	50	14.9290	0.3647
	60	22.7148	0.5549
	70	22.2891	0.5445
CPA-55 (Hydroorotic Acid)	10	100.6468	2.4587
	20	101.8257	2.4875
	30	69.1883	1.6902
	40	26.6200	0.6503
	50	20.0336	0.4894
	60	28.9901	0.7082
	70	23.4680	0.5733
CPA-39 (Fluorescein)	10	108.7069	2.6556
	20	100.7655	2.4616
	30	85.5295	2.0894
	40	55.5405	1.3568
	50	26.8779	0.6566
	60	24.9130	0.6086
	70	25.2405	0.6166
CPA-51 (Luminol)	10	101.2895	2.4744
	20	101.7970	2.4868
	30	85.9552	2.0998
	40	60.4118	1.4758
	50	38.2824	0.9352
	60	28.9983	0.7084
	70	28.8919	0.7058

Table 4. Percent of Survival of A549 Using Platinum Complex in MTT Assay

Complex	Concentration (in μ M)	Percent Survival	Average Absorbance
Cis-Pt	10	83.09927847	0.5299
	20	103.1095973	0.6575
	30	77.94510544	0.497033333
	40	74.69369001	0.4763
	50	57.14022853	0.364366667
	60	44.12933942	0.2814
	70	29.06932676	0.185366667
CPA-7	10		
	20	91.22258971	0.5817
	30	93.97740632	0.599266667
	40	45.5459529	0.290433333
	50	17.51164263	0.111666667
	60	3.538920018	0.022566667
	70	3.538920018	0.022566667
CPA-44 (Succinamide)	10	54.96042107	0.350466667
	20	23.37150871	0.149033333
	30	5.493951165	0.035033333
	40	4.929396716	0.031433333
	50	6.424420535	0.040966667
	60	4.8718958	0.031066667
	70	5.164627736	0.032933333

Table 5









CPA-7 	CPA-8 
CPA-8A 	CPA-9 
CPA-10 	CPA-12 (HK105) 
CPA-11 	CPA-14 

Table 5









CPA-15 	CPA-16 
CPA-17 	CPA-18 
CPA-19 	CPA-20 
CPA-26 	CPA-28 

Table 5









CPA-29 	 CPA-30 (HK112)
CPA-31 	CPA-32 
CPA-33  (HK108)	CPA-34 
CPA-35 	CPA-37 

Table 5







 <p>CPA-38</p>	 <p>CPA-39 (HK104)</p>
 <p>CPA-40</p>	 <p>CPA-41</p>
 <p>CPA-42 (HK107)</p>	 <p>CPA-46 (HK111)</p>

Table 5







 <p>CPA-43 (HK106)</p>	 <p>CPA-44</p>
 <p>CPA-45</p>	 <p>CPA-49</p>
 <p>CPA-50</p>	 <p>CPA-51 (HK110)</p>

Table 5







 <p>CPA-53</p>	 <p>CPA-54</p>
 <p>CPA-55 (HK109)</p>	 <p>CPA-56</p>
 <p>CPA-57</p>	 <p>JP4</p>

Table 5















JP5 	JP6A 
JP6B 	JP13A 
JP14B 	JP14C 

Table 5

JP14D 	 JP15
GD2 	GD3 
GD4 	GD6 
CPA-1 	CPA-3 

Example 2—XTT assay data for platinum complexes

The XTT assay is based on the conversion of the yellow tetrazalium salt XTT into an orange formazan dye by metabolically active cells. The orange formazan dye is soluble and can be photometrically quantitated using an ELISA plate reader. A decrease in the number of living cells results in a decrease in total metabolic activity which leads to a decrease in color formation. Platinum complexes of the present invention were tested in XTT assays using A549 cells to determine anti-cancer cell activity. The percent survival of cells versus platinum complex concentration is shown in graphical form in Figures 3 and 7.


10 Example 3—Reduction of CPA-7 platinum complex by glutathione

Figures 5A-C show the inertness of CPA-7 to glutathione reduction. In the figures, 20 μ m CPA-7 was added in PBS/20% DMSO with 10 mM glutathione. The readings were initiated in late evening where data points were collected every 10 minutes at the lambda max for CPA-7, 226 nm. The data shows slow reduction which then virtually stops during the night hours, and resumes the next day. This data demonstrates sensitivity to light and stability against GSH reduction. Data was collected on a Varian Cary 50 fitted with a fiberoptic probe in the kinetics mode. The Cary 50 uses a pulsed Xenon lamp with discontinuous irradiation between readings. A 25-mL volumetric flask was used for the solution with a magnetic stirring bar at slow speed.


20

Example 4—MTT assay data for platinum complexes

MTT assays are used for the quantitative determination of cellular proliferation and activation and for the quantitation of *in vitro* tumor cell sensitivity to anti-cancer compounds. The assay is based on the cleavage of the yellow tetrazolium salt MTT into purple colored formazan by metabolically active cells. Solubilized formazan product can be photometrically quantitated using an ELISA plate reader. A decrease in the number of living cells results in a decrease in total metabolic activity which leads to a decrease in color formation. Platinum complexes of the present invention were tested in MTT assays using A549 cells to determine anti-cancer cell activity. The results are shown in Tables 6, 7, 8, and 9 and Figures 8, 9, and 30 11. Table 6 shows percent survival of A549 cells and Table 7 shows the IC50 from the data in Table 6. Figures 8, 9, and 11 show percent survival versus platinum complex concentration in graphical form.

Table 6. MTT Assay: Percent of Survival of A549 Using cisplatin (Cis-Pt) or a Platinum Complex of formula:

Complex	Concentration (in μM)	Percent Survival	Average Absorbance
Cis-Pt	10	98.2423	2.3196
	20	98.3779	2.3228
	30	99.6400	2.3526
	40	90.2757	2.1315
	50	78.1288	1.8447
	60	46.7536	1.1039
	70	30.1470	0.7118
A = Safranin 1*	10	98.9412	2.3361
	20	100.1440	2.3645
	30	101.8000	2.4036
	40	85.0705	2.0086
	50	82.5674	1.9495
	60	69.5989	1.6433
	70	45.1484	1.0660
A = Safranin 2*	10	101.2791	2.3913
	20	101.2409	2.3904
	30	95.5826	2.2568
	40	83.2027	1.9645
	50	81.0131	1.9128
	60	67.3203	1.5895
	70	39.1682	0.9248
A = Methylene blue	10	100.5887	2.3750
	20	97.1030	2.2927
	30	95.3369	2.2510
	40	66.5029	1.5702
	50	36.1781	0.8542
	60	50.4468	1.1911
	70	40.2567	0.9505
A = 6-Aminonicotinamide	10	100.5548	2.3742
	20	103.0071	2.4321
	30	96.6245	2.2814
	40	72.9025	1.7213
	50	36.4999	0.8618
	60	32.7771	0.7739
	70	36.1526	0.8536
A = Methyl alpha-D-Mannopyranoside	10	104.1125	2.4582
	20	104.2311	2.4610
	30	91.2456	2.1544
	40	46.6096	1.1005
	50	28.0844	0.6631

Table 6. MTT Assay: Percent of Survival of A549 Using cisplatin (Cis-Pt) or a Platinum Complex of formula:

Complex	Concentration (in μM)	Percent Survival	Average Absorbance
	60	39.8967	0.9420
	70	35.9112	0.8479

* Two different isolates of the platinum (IV) complex substituted with Safranin were isolated (referred to herein as Safranin 1 and Safranin 2) and tested in the assay.

Table 7. Calculated IC50's from MTT Assay Data of Table 1


Complex	Calculated IC 50 (μM concentration)
Safranin 1*	78.60
Safranin 2*	72.57
Methylene blue	56.36
6-Aminonicotinamide	53.06
Methyl alpha-D-Mannopyranoside	50.10

Values in bold are outside the measured range.


All values are determined using a linear trend from percent survival vs. concentration data.

5

* Two different isolates of the platinum (IV) complex substituted with Safranin were isolated (referred to herein as Safranin 1 and Safranin 2) and tested in the assay.

Table 8. MTT Assay: Percent of Survival of A549 Using cisplatin (Cis-Pt) or a Platinum Complex of formula:


Complex	Concentration (in μM)	Percent Survival	Average Absorbance
Cis-Pt	10	100.9661	2.4665
	20	100.5199	2.4556
	30	92.8650	2.2686
	40	71.9432	1.7575
	50	52.5114	1.2828
	60	32.6293	0.7971

Table 8. MTT Assay: Percent of Survival of A549 Using cisplatin (Cis-Pt) or a Platinum Complex of formula:

Complex	Concentration (in μM)	Percent Survival	Average Absorbance
	70	27.5001	0.6718
A = Safranin 1*	10	100.3152	2.4506
	20	101.0725	2.4691
	30	100.9661	2.4665
	40	85.6236	2.0917
	50	62.0533	1.5159
	60	47.8079	1.1679
	70	35.5807	0.8692
A = Safranin 2*	10	101.3304	2.4754
	20	101.0766	2.4692
	30	94.1790	2.3007
	40	83.7284	2.0454
	50	62.7001	1.5317
	60	46.0928	1.1260
	70	35.4456	0.8659
A = Methylene blue	10	103.5613	2.5299
	20	88.6365	2.1653
	30	67.6900	1.6536
	40	30.7913	0.7522
	50	25.7972	0.6302
	60	31.5240	0.7701
	70	30.6234	0.7481
A = 6-Aminonicotinamide		101.1544	2.4711
	10		
	20	100.9947	2.4672
	30	81.4442	1.9896
	40	44.8770	1.0963
	50	26.5463	0.6485
	60	23.7873	0.5811
A = Methyl alpha-D-Mannopyranoside	70	25.7645	0.6294
	10	106.9098	2.6117
	20	99.6889	2.4353
	30	70.8789	1.7315
	40	25.2691	0.6173
	50	17.8886	0.4370
	60	20.5371	0.5017
	70	21.8552	0.5339

* Two different isolates of the platinum (IV) complex substituted with Safranin were isolated (referred to herein as Safranin 1 and Safranin 2) and tested in the assay.

Table 9. MTT Assay: Percent of Survival of A549 Using cisplatin (Cis-Pt) or a Platinum Complex of formula:



Complex	Concentration (in μM)	Percent Survival	Average Absorbance
Cis-Pt	10	83.09928	0.5299
	20	103.1096	0.6575
	30	77.94511	0.497033
	40	74.69369	0.4763
	50	57.14023	0.364367
	60	44.12934	0.2814
	70	29.06933	0.185367
A = Caffeine	10	72.23683268	0.460633333
	20	61.71416504	0.393533333
	30	31.61504914	0.2016
	40	13.94658583	0.088933333
	50	7.814897233	0.049833333
	60	9.571288852	0.061033333
	70	8.003082049	0.051033333
A = Safranin	10	77.35441421	0.493266667
	20	68.90177955	0.439366667
	30	34.45873081	0.219733333
	40	11.68836804	0.074533333
	50	8.301041342	0.052933333
	60	6.774653387	0.0432
	70	8.541499718	0.054466667
A = Theophylline	10	89.09505581	0.568133333
	20	60.59551085	0.3864
	30	33.86281222	0.215933333
	40	9.174009795	0.0585
	50	0.737057197	0.0047
	60	4.97644292	0.031733333
	70	-0.245685732	-0.001566667
A = N-acetyl glucosamine	10	96.89427097	0.617866667
	20	59.27298978	0.377966667
	30	27.21361538	0.173533333
	40	3.75846897	0.023966667
	50	6.225781006	0.0397
	60	8.661728906	0.055233333
	70	2.974365569	0.018966667

Example 5—XTT assay data for platinum complexes

The XTT assay is based on the conversion of the yellow tetrazolium salt XTT into an orange formazan dye by metabolically active cells. The orange formazan dye is soluble and can be photometrically quantitated using an ELISA plate reader. A decrease in the number of living cells results in a decrease in total metabolic activity which leads to a decrease in color formation. Platinum complexes of the present invention were tested in XTT assays using A549 cells to determine anti-cancer cell activity. The percent survival of cells versus platinum complex concentration is shown in graphical form in Figure 10.

10 Example 6—Inhibition of *in vitro* Stat3 DNA-binding Activity by HK-designated platinum complexes

Other platinum (IV) complexes were evaluated for inhibitory activity against STAT DNA-binding *in vitro*. Analysis by EMSA of nuclear extracts prepared from EGF-stimulated fibroblast that activates Stat1, Stat3 and Stat5 shows that preincubation (of extracts of equal 15 total protein) with different concentrations of platinum complexes for 30 min prior to incubation with ³²P-labeled hSIE probe results in a dose-dependent reduction in the levels of DNA-binding activities of Stat3 and Stat1 (Figures 12A and 12B).

It should be understood that the examples and embodiments described herein are for 20 illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

References

Published U.S. Patent Application No. 20030032594

5 Published U.S. Patent Application No. 20020120100

Published U.S. Patent Application No. 20020035243

10 Akira, S. (2000) "Roles of STAT3 defined by tissue-specific gene targeting" *Oncogene* 19:2607-2611.

15 Ardizzone, A., Antonelli, G., Grossi, F., Tixi, L., Cafferata, M., Rosso, R. (1999) "The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC)" *Ann. Oncol.* 10:S13-17.

20 Bowman, T., Garcia, R., Turkson, J., Jove, R. (2000) "STATs in oncogenesis" *Oncogene* 19:2474-2488.

25 Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D., Darnell, J. E., Jr. (1996) "Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma" *Proc. Natl. Acad. Sci. USA* 93:7673-7678.

30 Bromberg, J. F., Horvath, C. M., Besser, D., Lathem, W. W., Darnell, J. E., Jr. (1998) "Stat3 activation is required for cellular transformation by v-src" *Mol. Cell. Biol.* 18:2553-2558.

35 Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., Darnell, J. E., Jr. (1999) "Stat3 as an oncogene" *Cell* 98:295-303.

40 Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J. L., Nunez, G., Dalton, W. S., Jove, R. (1999a) "Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells" *Immunity* 10:105-115.

45 Catlett-Falcone, R., Dalton, W. S., Jove, R. (1999b) "STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription" *Curr. Opin. Oncol.* 11:490-496.

Coffer, P. J., Koenderman, L., de Groot, R. P. (2000) "The role of STATs in myeloid differentiation and leukemia" *Oncogene* 19:2511-2522.

50 Cuny, G. D. *et al.* (1999) "Photoactivated virucidal properties of tridentate 2,2'-dihydroxyazobenzene and 2-salicylideneaminophenol platinum pyridine complexes" *Bioorganic and Medicinal Chemistry Letters* 9(2):237-240.

Darnell, J. E., Jr., Kerr, I. M., Stark, G. R. (1994) "Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins" *Science* 264:1415-1421.

5 Darnell, J. E., Jr. (1997) "STATs and Gene Regulation" *Science* 277:1630-1635.

Epling-Burnette, P. K., Lui, J. H., Catlette-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., Jove, R., Loughran, T. P., Jr. (2001) "Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression" *J. Clin. Invest.* 107:351-362.

10 Fukada, T., Hibi, M., Yamanaka, Y., Takahashi-Tezuka, M., Fujitani, Y., Yamaguchi, T., Nakajima, K., Hirano, T. (1996) "Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis" *Immunity* 5:449-460.

15 Garcia, R., Jove, R. (1998) "Activation of STAT transcription factors in oncogenic tyrosine kinase signaling" *J. Biomed. Sci.* 5:79-85.

20 Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro-Cacho, C. A., Cox, C. E., Falcone, R., Fairclough, R., Parson, S., Laudano, A., Gazit, A., Levitzki, A., Kraker, A., Jove, R. (2001) "Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells" *Oncogene* 20:2499-2513.

25 Grandis, J. R., Drenning, S. D., Chakraborty, A., Zhou, M. Y., Zeng, Q., Pitt, A. S., Twardy, D. J. (1998) "Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro" *J. Clin. Invest.* 102:1385-1392.

30 Grandis, J. R., Drenning, S. D., Zeng, Q., Watkins, S. C., Melhem, M. F., Endo, S., Johnson, D. E., Huang, L., He, Y., Kim, J. D. (2000) "Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo" *Proc. Natl. Acad. Sci. USA* 97:4227-4232.

35 Hirano, T., Ishihara, K., Hibi, M. (2000) "Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors" *Oncogene* 19:2548-2556.

40 Kotenko, S. V., Pestka, S. (2000) "Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes" *Oncogene* 19:2557-2565.

Lin, T. S., Mahajan, S., Frank, D. A. (2000) "STAT signaling in the pathogenesis and treatment of leukemias" *Oncogene* 19:2496-2504.

45 Nielsen, M., Kaltoft, K., Nordahl, M., Ropke, C., Geisler, C., Mustelin, T., Dobson, P., Svejgaard, A., Odum, N. (1997) "Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines" *Proc. Natl. Acad. Sci. USA* 94:6764-6769.

5 Nielsen, M., Kaestel, C. G., Eriksen, K. W., Woetmann, A., Stokkedal, T., Kaltoft, K., Geisler, C., Ropke, C., Odum, N. (1999) "Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells" *Leukemia* 13:735-738.

10 Nitiss, J. L. (2002) "A copper connection to the uptake of platinum anticancer drugs" *Proc. Natl. Acad. Sci. USA* 99:13963-13965.

15 Persons, D. L., Yazlovitskaya, E. M., Cui, W., Pelling, J. C. (1999) "Cisplatin-induced Activation of Mitogen-activated Protein Kinases in Ovarian Carcinoma Cells: Inhibition of Extracellular Signal-regulated Kinase Activity Increases Sensitivity to Cisplatin" *Clin. Cancer Res.* 5:1007-1014.

20 Sanchez-Perez, I., Murguia, J. R., Perona, R. (1998) "Cisplatin induces a persistent activation of JNK that is related to cell death" *Oncogene* 16:533-540.

25 Schindler, C., Darnell, J. E., Jr. (1995) "Transcriptional responses to polypeptide ligands: the JAK-STAT pathway" *Annu. Rev. Biochem.* 64:621-651.

30 Smithgall, T. E., Briggs, S. D., Schreiner, S., Lerner, E. C., Cheng, H., Wilson, M. B. (2000) "Control of myeloid differentiation and survival by Stats" *Oncogene* 19:2612-2618.

35 Song, J. I., Grandis, J. R. (2000) "STAT signaling in head and neck cancer" *Oncogene* 19:2489-2495.

40 Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H., Schreiber, R. D. (1998) "How cells respond to interferons" *Annu. Rev. Biochem.* 67:227-264.

45 Toyoizumi, T., R. Mick, A. E. Abbas, E. H. Kang, L. R. Kaiser, K. L. Molnar-Kimber (1999) "Combined therapy with chemotherapeutic agents and herpes simplex virus type IICP34.5 mutant (HSV-1716) in human non-small cell lung cancer" *Human Gene Therapy* 10(18):17.

50 Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., de Groot, R. P., Jove, R. (1998) "Stat3 activation by Src induces specific gene regulation and is required for cell transformation" *Mol. Cell. Biol.* 18:2545-2552.

55 Turkson, J., Jove, R. (2000) "STAT proteins: novel molecular targets for cancer drug discovery" *Oncogene* 19:6613-6626.

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME 1 DE 2

NOTE: Pour les tomes additionnels, veillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**


THIS IS VOLUME 1 OF 2

NOTE: For additional volumes please contact the Canadian Patent Office.

Claims

We claim:


5 1. A platinum complex having the structure shown in formula I:



10

wherein



X and Y are, independently, any halogen, -NO₂, -ONO, or the structure:



15


or X and Y together form the structure:

20



25

or




30

R¹ is -NO₂ or -ONO;

R² is any halogen, -OH, -ONO, -ONO₂, -COR¹⁰, -OPO₃R¹⁰R¹¹, -OSO₃H, -OSeOOH, -SeOOH, -AsO₂, -OAsO₂, -NR¹⁰R¹¹, -NHR¹⁰R¹¹, -OOCR¹⁵, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl,

heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl, any of which can be optionally substituted with any halogen, -COOH, -OH, -NO₂, -NH₂, -N-alkyl, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, 5 cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl, or the structure:

10



any of which can be substituted with any halogen, -NH₂, -COOH, -OH, alkoxy, cycloalkoxy;

R³ is, independently, -NH₃, or -NHR⁷;

15 R⁷ is H, C₁₋₆ alkyl, alkoxy, or aryl, optionally substituted with -NO₂ or -COOH;

R¹⁰ and R¹¹ are, independently, H, -NH₂, -OH, -NHR⁷, CONHR⁷, CON(R⁷), C₁₋₆ alkyl, aryl, or heteroaryl, any of which can be optionally substituted with any halogen, -COOH, -OH, -NO₂, -NH₂, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, 20 heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl;

R¹⁵ is alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl, any of which can be optionally substituted with any halogen, -COOH, -OH, -NO₂, -NH₂, -N-alkyl, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl;

25 30 or a pharmaceutically acceptable salt thereof.

2. The platinum complex according to claim 1, wherein X and Y are, independently, selected from the group consisting of F, Cl, Br, and I.

3. The platinum complex according to claim 1, wherein X and Y are both Cl.


4. The platinum complex according to claim 1, wherein R¹ is -NO₂.

5

5. The platinum complex according to claim 1, wherein R³ is -NH₃.

6. A platinum complex having the structure shown in formula II:

10




15

wherein


X and Y are, independently, any halogen, or the structure:

20




or X and Y together form the structure:


25



or




or



30


50



5




10



R^4 is $-NO_2$ or $-ONO$;


R^5 is any halogen, $-OH$, $-ONO$, $-ONO_2$, $-COR^{10}$, $-OPO_3R^{10}R^{11}$, $-OSO_3H$, $-OSeOOH$,
 15 $-SeOOH$, $-AsO_2$, $-OAsO_2$, $-NR^{10}R^{11}$, $-NHR^{10}R^{11}$, $-OOCR^{15}$, alkyl, alkoxy, cycloalkyl,
 cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxy carbonyl, cycloalkyl carbonyl, heteroalkyl,
 heterocycloalkyl, heterocycloalkyl carbonyl, heteroaryl, aryl carbonyl, heteroaryl carbonyl,
 aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl,
 any of which can be optionally substituted with any halogen, $-COOH$, $-OH$, $-NO_2$, $-NH_2$, $-N-$
 20 alkyl, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxy carbonyl,
 cycloalkyl carbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkyl carbonyl, heteroaryl,
 aryl carbonyl, heteroaryl carbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,
 heterocycloalkoxy, or heterocycloalkoxycarbonyl, or the structure:

25




or X , Y , and R^5 together form the structure:

30



any of which can be substituted with any halogen, -NH₂, -COOH, -OH, or Y and R⁵ form the structures:

5



R⁶ is, independently, NH₂, or NH;

R⁷ is H, C₁₋₆ alkyl, alkoxy, or aryl, optionally substituted with -NO₂ or -COOH;

R⁸ and R⁹ are, independently, H, C₁₋₆ alkyl, or -OH, any of which can be optionally substituted with any halogen, -COOH, -OH, -NO₂, -NH₂, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl;

R¹⁰ and R¹¹ are, independently, H, -NH₂, -OH, -NHR⁷, CONHR⁷, CON(R⁷), C₁₋₆ alkyl, aryl, or heteroaryl, any of which can be optionally substituted with any halogen, -COOH, -OH, -NO₂, -NH₂, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl;

R¹² and R¹³ are, independently, H or C₁₋₆ alkyl, or R¹² and R¹³ together form an aryl, cycloalkyl, heterocycloalkyl, or heteroaryl, any of which can be optionally substituted with any halogen, -COOH, -OH, -NO₂, -NH₂, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl;

R¹⁵ is alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl, any of which can be optionally substituted with any halogen, -COOH, -OH, -NO₂, -NH₂, -N-alkyl, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl;

n is any integer from 0 to 6;
or a pharmaceutically acceptable salt thereof.



7. The platinum complex according to claim 6, wherein X and Y are,
5 independently, selected from the group consisting of F, Cl, Br, and I.

8. The platinum complex according to claim 6, wherein X and Y are both Cl.

9. The platinum complex according to claim 6, wherein R⁴ is -NO₂.


10. 10. The platinum complex according to claim 6, wherein R⁶ is -NH₂.

11. 11. A platinum complex having the structure shown in formula III or formula IV:




wherein

20 X and Y are, independently, any halogen, -NO₂, -ONO, or X and Y together form the structure:



or



25 R⁶ is, independently, NO₂, N, NH, or NH₂;



30 R⁸ and R⁹ are, independently, H, C₁₋₆ alkyl, or -OH, any of which can be optionally substituted with any halogen, -COOH, -OH, -NO₂, -NH₂, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl,

heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl; R¹² and R¹³ are, independently, H or C₁₋₆ alkyl, or R¹² and R¹³ together form an aryl, cycloalkyl, heterocycloalkyl, or heteroaryl, any of which can be optionally substituted with any halogen, -COOH, -OH, -NO₂, -NH₂, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkycarbonyl, alkoxy carbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl; n is any integer from 0 to 6;

10 or a pharmaceutically acceptable salt thereof.

12. A platinum complex having the structure of a complex selected from the group consisting of the complex designated CPA-1, CPA-3, CPA-7, CPA-8, CPA-8A, CPA-9, CPA-10, CPA-11, CPA-12, CPA-14, CPA-15, CPA-16, CPA-17, CPA-18, CPA-19, CPA-20, CPA-26, CPA-28, CPA-29, CPA-30, CPA-31, CPA-32, CPA-33, CPA-34, CPA-35, CPA-37, CPA-38, CPA-39, CPA-40, CPA-41, CPA-42, CPA-43, CPA-44, CPA-45, CPA-46, CPA-49, CPA-50, CPA-51, CPA-53, CPA-54, CPA-55, CPA-56, CPA-57, JP4, JP5, JP6A, JP6B, JP13A, JP14B, JP14C, JP14D, JP15, GD2, GD3, GD4, and GD6.

20 13. A platinum complex having the structure shown in formula V or formula VI:




wherein


X and Y are, independently, any halogen, -OH, H₂O, or -SO(CH₃)₂;

and A can be any of the following:


54




or




or



or




or




15


or




or




or



5




or




10

or

15




or




20

or

25




or



30

or


5




10

or

15




or



20

or

25



30

;

and wherein

R¹ is, independently, NH₂ or NH;

R² and R³ are, independently, H, -OH, C₁₋₆ alkyl, alkoxy, cycloalkyl, aryloxy, cycloalkoxy, aryl, heteroalkyl, heterocycloalkyl, heteroaryl, arylcarbonyl, and heteroarylcarbonyl, any of which can be optionally substituted with alkyl, alkoxy, cycloalkyl, aryloxy, cycloalkoxy, aryl, heteroalkyl, heterocycloalkyl, heteroaryl, arylcarbonyl, and heteroarylcarbonyl;

R⁴ and R⁵ are, independently, H or C₁₋₆ alkyl, alkoxy, cycloalkyl, aryloxy, cycloalkoxy, aryl, heteroalkyl, heterocycloalkyl, heteroaryl, arylcarbonyl, and heteroarylcarbonyl or R⁴ and R⁵ together form a cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryl, arylcarbonyl, and heteroarylcarbonyl, any of which can be optionally substituted with alkyl, alkoxy, cycloalkyl, aryloxy, cycloalkoxy, aryl, heteroalkyl, heterocycloalkyl, heteroaryl, arylcarbonyl, and heteroarylcarbonyl;


n is any integer from 0 to 6;

15 or a pharmaceutically acceptable salt thereof.


14. The platinum complex according to claim 13, wherein X and Y are, independently, selected from the group consisting of F, Cl, Br, and I.

20 15. The platinum complex according to claim 13, wherein X and Y are both Cl.

16. The platinum complex according to claim 13, selected from the group consisting of




59




,

10




20



30

60

5




10

15

20


25

30




,

,




,


5




10




15




20







25



30





25 17. A method for treating an inflammatory disorder in a patient, said method comprising administering an effective amount of a platinum complex of any of claims 1 to 16 to the patient.

18. The method according to claim 17, wherein the patient is a mammal.

30

19. The method according claim 17, wherein the patient is a human, monkey, chimpanzee, ape, dog, cat, horse, cow, or pig.

20. The method according to claim 17, wherein said platinum complex is encapsulated in a liposome moiety or said platinum complex comprises a protein or nucleic acid that targets delivery of the platinum complex to a cell.

5 21. A method for treating or preventing a viral, bacterial, or parasitic infection in a patient, said method comprising administering an effective amount of a platinum complex of any of claims 1 to 16 to the patient.

10 22. The method according to claim 21, wherein the patient is a mammal.

23. The method according to claim 21, wherein the patient is a human, monkey, chimpanzee, ape, dog, cat, horse, cow, or pig.

15 24. The method according to claim 21, wherein said parasitic infection is caused by an organism selected from the group consisting of *Leishmania*, *Toxoplasma*, *Schistosoma*, *Plasmodium*, *Trypanosoma*, *Entamoeba*, *Giardia*, *Trichomonas*, *Ascaris*, *Trichuris*, *Enterobius*, *Necator*, *Ancylostoma*, *Strongyloides*, and *Trichinella*.

20 25. The method according to claim 21, wherein the patient has a disease condition selected from the group consisting of leishmania, toxoplasmosis, schistosomiasis, trypanosomiasis, pneumocystis, malaria, and trichinosis.

25 26. The method according to claim 21, wherein said bacterial infection is caused by an organism selected from the group consisting of *Staphylococcus*, *Streptococcus*, *Salmonella*, *Bacillus*, *Clostridium*, *Pseudomonas*, *Neisseria*, *Mycobacterium*, and *Yersinia*.

30 27. The method according to claim 21, wherein said viral infection is caused by a virus selected from the group consisting of human immunodeficiency virus (HIV), human T cell leukemia virus (HTLV), Papillomavirus (e.g., human papilloma virus), Polyomavirus (e.g., SV40, BK virus, DAR virus), orthopoxvirus (e.g., variola major virus (smallpox virus)), EBV, herpes simplex virus (HSV), hepatitis virus, Rhabdovirus (e.g., Ebola virus) and cytomegalovirus (CMV).

28. A method for synthesis of a platinum complex, said method comprising:

a) mixing cisplatin in water and an organic solvent;

b) mixing into the mixture of step (a) a ligand capable of bonding to the platinum of cisplatin to form the platinum complex product;

5 c) contacting the mixture of step (b) with nitrogen dioxide gas; and

d) separating the platinum complex product from the solvent.

29. The method according to claim 28, wherein the organic solvent is dichloroethane or hexane.

10

30. The method according to claim 28, wherein the platinum complex product is separated from the solvent by evaporation of the solvent.

15 31. The method according to claim 28, wherein following step (d), the platinum complex product is further purified.

32. The method according to claim 31, wherein the platinum complex product is further purified by recrystallization in a solvent.

20 33. The method according to claim 31, wherein the platinum complex product is further purified by adsorption on a silica column or by high performance liquid chromatography (HPLC).




FIG. 1




FIG. 2

3/14




FIG. 3

4/14




FIG. 4

5/14




FIG. 5A

6/14




FIG. 5C

FIG. 5B




FIG. 6




FIG. 7

9/14




FIG. 8

10/14




FIG. 9

11/14




FIG. 10

12/14





FIG. 11


13/14


Fig. 12A-- EMSA analysis showing inhibition of STAT DNA-binding activity



14/14

Fig. 12B--EMSA analysis showing inhibition of STAT DNA-binding activity





(I)